MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has agreed to acquire Cidara Therapeutics in a $9.2bn deal, adding a new long-lasting infectious disease drug technology to…
14 Nov 2025
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
Eli Lilly and Novo Nordisk have rebutted claims that they have partnered with telehealth provider Mangoceuticals, sending the online company's shares back down after an initial rise. On 13 November,…
14 Nov 2025
Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy
Kyowa Kirin’s bet on Kura Oncology appears to have paid off, as the companies have secured approval for their jointly developed drug, Komzifti (ziftomenib). Following the US Food and Drug…
14 Nov 2025
General Proximity and Daiichi Sankyo link on oncology
General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. Daiichi Sankyo entered the collaboration through its Research Institute, located in…
14 Nov 2025
Eisai and Biogen report Leqembi’s MHRA approval for Alzheimer’s
Eisai and Biogen have announced the UK Medicines and Healthcare products Regulatory Agency's (MHRA) approval for Leqembi (lecanemab) for intravenous (IV) maintenance dosing once every four weeks to treat early…
13 Nov 2025
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle
Metagenomi will slash a quarter of its workforce and switch up its CEO as part of efforts to extend its cash runway to Q4 2027. The layoffs come via the…
13 Nov 2025
FDA unveils new pathway to usher bespoke therapies to market
The US Food and Drug Administration (FDA) has created a new pathway to bring personalised therapies to market that can bypass certain requirements, using the success of Baby KJ’s treatment…